CRISPR Therapeutics (CRSP) News Today $40.48 -0.24 (-0.59%) (As of 05:45 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period JMP Securities Reiterates "Market Outperform" Rating for CRISPR Therapeutics (NASDAQ:CRSP)December 23 at 3:13 AM | americanbankingnews.comThis Beaten-Down Biotech Stock Just Got Some Good News: Time to Buy?December 22 at 12:25 PM | fool.com1 big new Green Flag for CRISPR Therapeutics' StockDecember 20 at 9:30 AM | fool.comCRISPR Therapeutics' (CRSP) "Market Outperform" Rating Reaffirmed at JMP SecuritiesJMP Securities reiterated a "market outperform" rating and issued a $86.00 price objective on shares of CRISPR Therapeutics in a research note on Friday.December 20 at 9:08 AM | marketbeat.comCRISPR Therapeutics (NASDAQ:CRSP) Hits New 12-Month Low - Time to Sell?CRISPR Therapeutics (NASDAQ:CRSP) Sets New 12-Month Low - Should You Sell?December 19, 2024 | marketbeat.com2 Growth Stocks That Could Rocket Higher in 2025: Are They Right for Your Portfolio?December 17, 2024 | fool.comCRISPR Therapeutics AG (NASDAQ:CRSP) Sees Significant Decline in Short InterestCRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) was the target of a significant drop in short interest in November. As of November 30th, there was short interest totalling 18,150,000 shares, a drop of 6.4% from the November 15th total of 19,390,000 shares. Based on an average daily volume of 1,430,000 shares, the short-interest ratio is presently 12.7 days.December 16, 2024 | marketbeat.comCRISPR Therapeutics AG (NASDAQ:CRSP) Shares Acquired by State Street CorpState Street Corp lifted its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 25.0% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,992,988 shares of the company's stock after purchasing an additional 599,304 shares duDecember 15, 2024 | marketbeat.com3 Things You Need to Know if You Buy CRISPR Therapeutics TodayDecember 14, 2024 | fool.comCRISPR Therapeutics (NASDAQ:CRSP) Reaches New 12-Month Low - Time to Sell?CRISPR Therapeutics (NASDAQ:CRSP) Reaches New 52-Week Low - Here's WhyDecember 13, 2024 | marketbeat.comZacks Research Has Bearish Estimate for CRSP Q2 EarningsDecember 13, 2024 | americanbankingnews.comEquities Analysts Offer Predictions for CRSP FY2024 EarningsDecember 13, 2024 | americanbankingnews.comResearch Analysts Offer Predictions for CRSP Q2 EarningsCRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Stock analysts at Zacks Research reduced their Q2 2025 earnings estimates for CRISPR Therapeutics in a research note issued on Monday, December 9th. Zacks Research analyst R. Department now forecasts that the company will earn ($1.48) per shareDecember 12, 2024 | marketbeat.comIs CRISPR Therapeutics AG (CRSP) the Worst ARK Stock to Buy According to Short Sellers?December 11, 2024 | uk.finance.yahoo.comWhat is William Blair's Forecast for CRSP FY2024 Earnings?CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Equities research analysts at William Blair issued their FY2024 earnings per share (EPS) estimates for shares of CRISPR Therapeutics in a report issued on Monday, December 9th. William Blair analyst S. Corwin forecasts that the company will earDecember 11, 2024 | marketbeat.comCrispr Therapeutics AG (CRSP) Gets a Hold from Evercore ISIDecember 10, 2024 | markets.businessinsider.comCRISPR Therapeutics' (CRSP) "Buy" Rating Reaffirmed at Chardan CapitalChardan Capital reiterated a "buy" rating and set a $94.00 price objective on shares of CRISPR Therapeutics in a report on Tuesday.December 10, 2024 | marketbeat.comCRISPR Therapeutics Presents Data at the 2024 American Society of Hematology (ASH) Annual MeetingDecember 9, 2024 | finance.yahoo.comCRISPR Therapeutics Presents Data at the 2024 American Society of Hematology (ASH) Annual MeetingDecember 9, 2024 | globenewswire.comXTX Topco Ltd Has $1.41 Million Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)XTX Topco Ltd boosted its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 294.0% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 30,022 shares of the company's stock after purchasing an additional 22,402 shares duDecember 9, 2024 | marketbeat.comMain Management ETF Advisors LLC Takes Position in CRISPR Therapeutics AG (NASDAQ:CRSP)Main Management ETF Advisors LLC purchased a new stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) in the third quarter, according to its most recent filing with the SEC. The firm purchased 14,744 shares of the company's stock, valued at approximately $693,000. A number of otherDecember 8, 2024 | marketbeat.com2 Biotech Stocks to Buy Hand Over Fist in DecemberDecember 7, 2024 | fool.comCRISPR Therapeutics (CRSP) Upgraded to Buy: What Does It Mean for the Stock?December 6, 2024 | msn.comBenjamin Edwards Inc. Has $1.54 Million Stake in CRISPR Therapeutics AG (NASDAQ:CRSP)Benjamin Edwards Inc. raised its position in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 13,640.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 32,703 shares of the company's stock after purchasing an additionDecember 6, 2024 | marketbeat.comCRISPR Therapeutics AG (NASDAQ:CRSP) CEO Samarth Kulkarni Sells 15,000 SharesDecember 5, 2024 | insidertrades.com3 of the Best Growth Stocks You Can Buy for Less than $100December 5, 2024 | fool.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 17,632 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lowered its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 2.5% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 676,326 shares of the company's stocDecember 5, 2024 | marketbeat.comBNP Paribas Financial Markets Sells 48,467 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)BNP Paribas Financial Markets reduced its position in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 35.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 87,956 shares of the company's stock after sDecember 5, 2024 | marketbeat.comFmr LLC Has $111.63 Million Position in CRISPR Therapeutics AG (NASDAQ:CRSP)Fmr LLC increased its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 1.0% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 2,376,166 shares of the company's stock after purchasing an additional 23,075 shares during the period. FDecember 5, 2024 | marketbeat.comCRISPR Therapeutics: Strong Balance Sheet Supports Ambitious Plans Amid Slow GrowthDecember 3, 2024 | seekingalpha.comCRISPR Therapeutics AG (NASDAQ:CRSP) Receives Consensus Rating of "Hold" from BrokeragesCRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) has been assigned a consensus recommendation of "Hold" from the nineteen brokerages that are presently covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine havDecember 3, 2024 | marketbeat.comBaker BROS. Advisors LP Acquires 743,075 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)Baker BROS. Advisors LP grew its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 743.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 843,075 shares of the company's stock afteDecember 2, 2024 | marketbeat.comMeet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More than 65%November 30, 2024 | fool.comFY2024 Earnings Estimate for CRSP Issued By Zacks ResearchCRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Analysts at Zacks Research upped their FY2024 earnings per share estimates for shares of CRISPR Therapeutics in a research note issued to investors on Tuesday, November 26th. Zacks Research analyst R. Department now anticipates that the companyNovember 28, 2024 | marketbeat.comLoomis Sayles & Co. L P Sells 60,946 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)Loomis Sayles & Co. L P lessened its stake in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 6.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 945,267 shares of the company's stock after selling 60,94November 26, 2024 | marketbeat.comDown 47% Since March, Is CRISPR Therapeutics Stock a Buy on the Dip?November 24, 2024 | fool.com3 Monster Stocks in the MakingNovember 23, 2024 | fool.comCRISPR Therapeutics AG (CRSP) Jefferies London Healthcare Conference (Transcript)November 20, 2024 | seekingalpha.comTruist Financial Keeps Their Buy Rating on Crispr Therapeutics AG (CRSP)November 20, 2024 | markets.businessinsider.comCRISPR Therapeutics AG (CRSP): Among the Best Genomics Stocks to Buy Right NowNovember 20, 2024 | yahoo.comCRISPR Therapeutics AG (NASDAQ:CRSP) Sees Large Increase in Short InterestCRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) saw a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 18,590,000 shares, an increase of 5.7% from the October 15th total of 17,590,000 shares. Based on an average daily trading volume, of 1,160,000 shares, the short-interest ratio is currently 16.0 days.November 19, 2024 | marketbeat.comCrispr Therapeutics management to meet with Piper SandlerNovember 19, 2024 | markets.businessinsider.comCathie Wood’s ARK Investment bought 176K shares of Crispr Therapeutics todayNovember 19, 2024 | markets.businessinsider.comDeciphering Disruption: Inside Cathie Wood's Latest Plays (CRSP)Cathie Wood's recent stock market activity offers a glimpse into her evolving investment strategy and the potential of disruptive technologies.November 18, 2024 | marketbeat.com2 Top Biotech Stocks to Buy Now and Hold For 5 Years or MoreNovember 16, 2024 | fool.comCathie Wood’s ARK Investment bought 178.1K shares of Crispr Therapeutics todayNovember 15, 2024 | markets.businessinsider.comCRISPR Therapeutics AG (CRSP) Guggenheim Inaugural Healthcare Innovation Conference (Transcript)November 15, 2024 | seekingalpha.comWhere Will CRISPR Therapeutics Be in 3 Years?November 15, 2024 | fool.comCRISPR Therapeutics to Present at the Jefferies London Healthcare ConferenceNovember 14, 2024 | globenewswire.comSamarth Kulkarni Sells 30,000 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) StockNovember 14, 2024 | insidertrades.com Get CRISPR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter. Email Address Forced out of retirement by these trades (Ad)You know, I never really intended to get in front of a camera and tell folks about a new market paradigm that I discovered. Even though I have a bright and shiny “resume,” I thought I’d left investing behind forever. And I was more than happy to be a stay-at-home dad… But then I discovered Gamma Pockets… and everything changed Make sure to check out Gamma Pockets HERE while it’s still widely available CRSP Media Mentions By Week CRSP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRSP News Sentiment▼0.810.59▲Average Medical News Sentiment CRSP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRSP Articles This Week▼810▲CRSP Articles Average Week Get CRISPR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Neurocrine Biosciences News Bio-Techne News Vaxcyte News Qiagen News Exelixis News Repligen News Revolution Medicines News Halozyme Therapeutics News Krystal Biotech News ADMA Biologics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CRSP) was last updated on 12/23/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CRISPR Therapeutics AG Please log in to your account or sign up in order to add this asset to your watchlist. Share CRISPR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
